December 8, 2009 (FinancialWire) — Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced that Adelene Q. Perkins will become the company’s president and chief executive officer, and join the company’s board of directors, effective January 1, 2010 in accordance with an existing management succession plan.

Steven H. Holtzman, Infinity’s founder, and current chair and chief executive officer, will continue full-time involvement with the company as Executive chair of its board of directors.

Perkins has over 25 years of international business and corporate strategy experience in the biopharmaceutical industry, focused on licensing and business development, strategic finance, product life cycle management, and leading high-caliber, cross-functional teams. Since joining Infinity in 2002, she has played an integral role in developing Infinity’s strategic plan, leading the company in its transition from a platform to a product-based organization. She has also been the principal figure in structuring, executing and managing all of Infinity’s innovative strategic relationships, including its global alliance with Purdue Pharmaceutical Products L.P. and Mundipharma International Corp. Ltd.

Holtzman has been the chair and chief executive officer of Infinity since its founding in 2001. As Executive chair, Holtzman will remain actively involved in Infinity’s major strategic initiatives, while also playing a key role in external relations and the company’s internal leadership development programs.

Perkins currently serves as Infinity’s president and Chief Business officer. In this capacity, she has executive responsibility for all of Infinity’s corporate and business functions, including corporate, product and business development, commercial affairs, corporate communications, finance, human resources, and legal affairs. More recently, Perkins has led an initiative to establish the company’s strategic commercial vision and objectives.

Prior to joining Infinity, Perkins served as vice president of Business and Corporate Development at TransForm Pharmaceuticals. Prior to TransForm, she was vice president of Emerging Businesses and the cofounder and general manager of the DiscoverEase(tm) Business Unit at Genetics Institute. Perkins began her career at Bain & company, an international strategy consulting firm, where she provided strategic and operational advice to clients in the healthcare industry. She holds an M.B.A. from Harvard Business School and a B.S. in Chemical Engineering from Villanova University. Perkins was recently named a 2009 “Best Executive” by the Stevies Awards for Women.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279). The most recently issued reports and/or recorded webcasts include Aria International Holdings, Inc. (OTCBB: ARAH), Continental Materials Corp. (AMEX: CUO), Darling International, Inc. (NYSE: DAR), Document Security Systems, Inc. (AMEX: DMC), and Juhl Wind, Inc. (OTCBB: JUHL).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.